GDC-0449 (Vismodegib) - Hedgehog Antagonist. CAS# 879085-55-9 094 nonspecific cytotoxicity independent of Stat3

nonspecific cytotoxicity independent of Stat3 activation status

CC1(N)CCN(CC1)C1=CN=C(C2=CC=CC(Cl)=C2Cl)C(N)=N1

GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1

Studies showed that it has more potent activity than the recombinant Hh protein in activating Smo and hedgehog pathway

GDC-0449 (Vismodegib) - Hedgehog Antagonist. CAS# 879085-55-9 094 nonspecific cytotoxicity independent of Stat3Vismodegib (GDC 0449), CAS No. 879085 55 9, is a potent and specific hedgehog pathway inhibitor with an IC50 of 3 nM. It has been approved by FDA to treat BCC, and also in multiple clinical trials to treat advanced solid tumors. It blocks the activities of the Hedgehog ligand cell surface receptors PTCH and or SMO and suppressing Hedgehog signaling. It prevents multiple ATP binding cassette (ABC) transporters. GDC 0449 also exhibited efficacy in